Pseudorabies virus three-gene deleted strain and application thereof
By constructing the three gene deletion strain of pseudorabies virus epidemic strain gG/gI/gE, a gene deletion inactivated vaccine was prepared, which solved the problem of insufficient protection of existing vaccines on pseudorabies virus mutant strains, and achieved effective prevention of pseudorabies virus Control and efficient immunity effects.
Patent Information
- Application Number
- CN202410785398.8
- Authority / Receiving Office
- CN · China
- Patent Type
- Applications(China)
- Current Assignee / Owner
- Filing Date
- 2024-06-18
- Publication Date
- 2024-11-12
AI Technical Summary
The existing pig pseudorabies vaccines have insufficient protection against pseudorabies virus variants and cannot effectively prevent and control the currently prevalent pseudorabies virus.
A three-gene deletion strain of pseudorabies virus epidemic strain gG/gI/gE was constructed, and a gene deletion inactivated vaccine with different dosage forms and different immune pathways was prepared. HeN21-ΔgG/gI/ was generated by knockout technology of the virus. gE strains are used to develop effective gene deletion inactivated vaccines.
The vaccine showed safety and efficiency in mouse and piglet immunization tests, able to produce neutralizing antibodies in a short time, providing a 60% clinical protection rate, significantly improving its resistance to pseudorabies virus variant strains.
Smart Images

Figure CN118931850A_ABST
Abstract
Description
Technical Field
[0001] The invention belongs to the technical field of animal virology and genetic engineering, and specifically relates to the construction and application of a pseudorabies virus epidemic strain gG / gI / gE / three-gene deletion strain. Technical Background
[0002] Swine pseudorabies (Pseudorabies, PR) is a serious economic infectious disease in the pig farming industry caused by pseudorabies virus (Pseudorabies virus, PRV). The prevalence of this disease in my country has mainly gone through two stages. The first large-scale epidemic occurred in the 1970s. The classic strains caused high mortality in piglets and reproductive disorders in breeding pigs. The use of vaccines equipped with corresponding diagnostic preparations prevented and controlled the spread of the disease. Subsequently, around 2011, PRV mutant strains appeared, which showed greater virulence than the classic strains, and vaccines prepared from classic strains could not effectively prevent and control them. In 2021, the research team of the College of Animal Science and Technology, the College of Veterinary Medicine and the Collaborative Innovation Center for Healthy Pig Breeding in Hubei Province isolated a PRV mutant strong strain HeN21 from a place in Henan Province, which can cause severe respiratory infections and death in older fat pigs. The present invention uses the HeN21 strain as the parent, deletes the gG / gI / gE genes, prepares gene-deleted inactivated vaccines in different dosage forms, explores the safety and immune efficacy of these two vaccines on mice and piglets through different immunization pathways, and provides technical reserves for pseudorabies virus variant vaccines.
[0003] The research group of the Collaborative Innovation Center for Healthy Swine Breeding where the applicant is located has been engaged in domestic PRV epidemiological investigation and mechanism research. The present invention screened out the PRV HeN21 strain from the PRV strains isolated in the laboratory in recent years. Studies have shown that it is closely related to the pseudorabies virus variant strain, and its pathogenicity to mice and pigs is significantly higher than that of the classical strain. It is an ideal candidate strain for the development of a gene-deficient vaccine that can effectively prevent and control the current pseudorabies epidemic. Summary of the invention
[0004] The first purpose of the present invention is to construct a pseudorabies virus epidemic strain gG / gI / gE triple gene deletion strain, and prepare gene deletion inactivated vaccines of different dosage forms and different immune pathways, so as to overcome the shortcomings of the existing porcine pseudorabies vaccine in insufficient protection against the current pseudorabies virus variants.
[0005] The second object of the present invention is to provide a method for constructing the gG / gI / gE triple gene deletion strain of the pseudorabies virus epidemic strain.
[0006] The third object of the present invention is to provide the clinical application effect of the pseudorabies virus epidemic strain gG / gI / gE triple gene deleted inactivated vaccine.
[0007] The present invention is achieved through the following technical solutions:
[0008] The present invention obtained a strain of pseudorabies virus PRV HeN21 from suspected swine pseudorabies disease materials by microbiological separation method during the epidemiological investigation of pseudorabies virus. Pseudorabies Virus PRV HeN21 was sent to China. Wuhan. Wuhan University China Type Culture Collection (CCTCC) on June 11, 2024, with the collection number CCTCCNO: V202424. Sequence determination of gB, gC and gE of the pseudorabies virus found that it was closely related to the currently prevalent pseudorabies virus variant. Animal regression experiments showed that the strain had strong virulence and good immunogenicity, and was suitable as a candidate strain for vaccine research.
[0009] The pseudorabies virus epidemic strain gG / gI / gE triple gene deletion strain constructed by the present invention is obtained by knocking out some genes of gG, gI / gE (commonly known as glycoprotein) in the genome of the strain. The specific knocked-out gene fragments are as follows:
[0010] The nucleotide sequence of the deleted portion of the gG gene in the deletion strain of the present invention is as follows (the sequence is the same as the sequence shown in SEQ ID NO: 1 in the sequence table):
[0011]
[0012] The gI / gE gene in the deletion strain of the present invention is deleted with a partial nucleotide sequence as follows (the sequence is the same as the sequence shown in SEQ ID NO: 2 in the sequence table):
[0013]
[0014] The applicant named the constructed pseudorabies virus epidemic strain gG / gI / gE triple gene deletion strain as Pseudorabies Virus HeN21-ΔgG / gI / gE, and sent it to the China Type Culture Collection (CCTCC) of Wuhan University, Wuhan, China on June 11, 2024, with the preservation number CCTCC NO: V202464.
[0015] The microbiological morphology and physiological characteristics of the pseudorabies virus epidemic strain with gG / gI / gE triple gene deletion are as follows (also known as microbiological characteristics):
[0016] The HeN21-ΔgG / gI / gE strain was continuously passaged in PK-15 cells for 20 times, and PCR identification, fragment sequencing and titer determination were performed every 5 generations. The results showed that the gG / gI / gE site was stably deleted, and no base mutation or insertion occurred. During the continuous cell passage, the titer of HeN21-ΔgG / gI / gE remained in a relatively stable range (10 8.0 ~10 8.59 TCID 50 ). The results of the indirect immunofluorescence test showed that HeN21-ΔgG / gI / gE did not emit gE-specific fluorescence under a fluorescence microscope, which can achieve serological differential diagnosis from wild-type viruses. The HeN21-ΔgG / gI / gE strain was infected with PK-15 cells at a dose of 1MOI, and the virus titer was measured at different time periods. The results showed that the proliferation characteristics of the HeN21-ΔgG / gI / gE strain were similar to those of the parental strain. PK-15 cells were infected with a 1MOI dose of HeN21-ΔgG / gI / gE to determine the plaque-forming ability. The results showed that the average plaque area of HeN21-ΔgG / gI / gE was 25842.1μm 2 The average plaque area of the parent virus was 31504.9 μm 2 Compared with the former, the plaque ability of the two is reduced to a certain extent. 2 -10 4 TCID 50 The LD 50 The results showed that HeN21-ΔgG / gI / gE was 10 2.87 TCID 50 , with 10 of the parental toxic 2.63 TCID 50Compared with the control group, the toxicity of the PRV strain was not significantly reduced, indicating that the toxicity of the PRV strain without TK gene deletion was still strong. Based on a series of biological characteristics of the HeN21-ΔgG / gI / gE strain, the inactivated vaccine of HeN21-ΔgG / gI / gE was selected for preparation.
[0017] Animal experiments on the inactivated vaccine with triple gene deletion of pseudorabies virus epidemic strain gG / gI / gE:
[0018] Twenty-five healthy Balb / c mice aged 4-6 weeks were randomly divided into five groups and immunized subcutaneously with inactivated HeN21-ΔgG / gI / gE, Bartha K-61 and commercial PRV variant vaccine at 10 7 TCID 50 The 9 4-6 week old pseudorabies gB and gE negative piglets were divided into 3 groups. The first group was injected intramuscularly with 2×10 8.0 TCID 50 The second group received 2×10 HeN21-ΔgG / gI / gE inactivated freeze-dried vaccine without needle injection. 8.0 TCID 50 The third group was inoculated with DMEM as the uninfected control group. Symptoms were observed daily after inoculation, and the number of deaths and survivals was recorded for 14 days. The experimental results showed that high-dose HeN21-ΔgG / gI / gE gene-deficient inactivated vaccine was safe for mice and piglets and could be used in further clinical practice.
[0019] In the mouse immunogenicity test, 20 healthy SPF Balb / c mice aged 4-6 weeks were divided into four groups, with 5 mice in each group. 1×10 7 TCID 50The mice were given a dose of HeN21-ΔgG / gI / gE gene-deficient inactivated vaccine and BarthaK-61 inactivated vaccine, and a commercial PRV variant inactivated vaccine was set as a control, and the last group was used as a blank control. A booster immunization was performed 14 days after the first immunization, and a lethal dose of HeN21 was challenged on the 28th day. The mice were then observed for 14 days, during which serum was collected every 7 days to detect the levels of gB, gE, and neutralizing antibodies in the mice. The test results showed that the gE antibody level remained negative for 14 days after the virus attack, indicating that the high-dose inactivated vaccine can completely block the wild-type pseudorabies virus infection within 2 weeks of the virus attack; the gB antibody level began to turn positive 14 days after the first immunization and continued until the last day of the observation period; the neutralizing antibody levels of the three immunized groups continued to rise during the immunization period, and produced 1:178, 1:130, and 1:162 neutralizing antibodies respectively on the 42nd day of immunization. The pathological section results showed that there were no obvious lesions in the three immunized groups, while the virus attack control group showed typical pathological changes of pseudorabies virus infection.
[0020] In the piglet immunogenicity test, 25 healthy PRV-negative piglets aged 4-6 weeks were divided into 5 groups. The first group was injected with 2×10 HeN21-ΔgG / gI / gE inactivated freeze-dried vaccine without needle. 8 TCID 50 The second group was immunized with HeN21-ΔgG / gI / gE inactivated vaccine 2×10 8 TCID 50 , the third group was intramuscularly immunized with commercial PRV variant inactivated vaccine 2×10 8 TCID 50 , and set up virus-challenging control and blank control. 21 days after the first immunization, booster immunization was performed, and 14 days after the booster immunization, 2×10 HeN21 strains were intranasally infected. 7 TCID 50 / head, blood was collected before vaccination, 21d and 35d after vaccination, and every 3-4d after challenge to monitor serum antibody levels. Anticoagulated blood, throat swabs and anal swabs were collected according to the time period, and weighed, measured temperature, and scored for clinical symptoms. The gB ELISA antibody results showed that the three groups of vaccine test pigs showed strong gB positivity on the 21st day after vaccination, and the gB positivity value reached the highest level in the second week of challenge, and continued until the last day of the experimental observation, still maintaining a strong positive value. The gE ELISA test results showed that the commercial vaccine immunization group began to turn positive for gE antibodies one week after challenge, while the HeN21-ΔgG / gI / gE intramuscular injection group began to turn positive in the third week after challenge, and the HeN21-ΔgG / gI / gE needle-free group remained gE negative throughout, and only weak gE antibodies were detected on the last day of the observation period. Judging from the neutralizing antibody level, temperature change curve after virus attack, average weight gain level during the test period, and tissue viral load results, the HeN21-ΔgG / gI / gE needle-free group performed the best, with no fever within one week of virus attack; the highest average weight gain within 21 days; the neutralizing antibody level reached 1:256 one week earlier than other immunization groups; all three groups were able to effectively resist the attack of strong PRV strains, providing a 60% clinical protection rate. In summary, the latest pseudorabies variant strain gene deletion, inactivated freeze-dried, and needle-free intradermal immunization may be used as a new immunization method in pig farms. BRIEF DESCRIPTION OF THE DRAWINGS
[0021] Figure 1 : The pcDNA3.1(+) vector used in the present invention and the pcDNA3.1(+)-△gG / gI / gE vector constructed with it as the backbone map A: pcDNA3.1(+); B: pcDNA3.1(+)-△gG / gI / gE.
[0022] Figure 2 : PCR identification diagram of the deletion of the recombinant plasmid pcDNA3.1(+)-ΔgG / gI / gE of the present invention. Explanation of the accompanying symbols: M: DL2000 DNA Marker; 1, 4: pcDNA3.1(+)-ΔgG / gI / gE; 2, 5: HeN21 positive control; 3, 6: blank control.
[0023] Figure 3 : The purification and identification results of the HeN21-ΔgG / gI / gE gene-deficient strain of the present invention. Explanation of the accompanying symbols: M: DL2000 DNA Marker; 1-8, 12-19: HeN21ΔgG / gI / gE purified plaques; 9, 20: HeN21 positive control; 10, 21: pcDNA3.1(+)-ΔgG / gI / gE plasmid control; 11, 22: blank control.
[0024] Figure 4:HeN21-ΔgG / gI / gE deletion position genetic stability identification diagram. Figure 4 Figure A shows: Determination of the toxicity of HeN21ΔgG / gI / gE triple gene deletion virus in serial passages; Figure 4 Figure B shows the genetic stability of the HeN21ΔgG / gI / gE triple gene deletion strain, and the accompanying figure numbers are as follows: wherein the markers 1-5, 9-13: f0, f5, f10, f15 and f20 represent the genome of HeN21-ΔgG / gI / gE respectively; the markers 6 and 14 represent the pcDNA3.1(+)-ΔgG / gI / gE plasmid; the markers 7 and 15 represent the blank control group; Figure 4 Figure C shows the sequencing results of the HeN21-ΔgG / gI / gE gene-deficient strain fragment.
[0025] Figure 5 :HeN21-ΔgG / gI / gE indirect immunofluorescence results. Figure 5 Figure A is HeN21-ΔgG / gI / gE; Figure 5 Figure B in the figure is HeN21; Figure 5 Figure C is the blank control group.
[0026] Figure 6 : Proliferation curves of HeN21-ΔgG / gI / gE strain and HeN21.
[0027] Figure 7 : Plaque morphology and plaque area of HeN21-ΔgG / gI / gE strain and HeN21 strain. Figure 7 The left picture in the figure shows the plaque morphology of PRVHeN21-ΔgG / gI / gE and HeN21; Figure 7 The right figure in the figure is a comparison of the plaque areas of PRV HeN21-ΔgG / gI / gE and HeN21.
[0028] Figure 8 :Results of the safety test of HeN21-ΔgG / gI / gE on mice.
[0029] Fig. 9 : Detection results of neutralizing antibody levels in mice after HeN21-ΔgG / gI / gE immunization.
[0030] Fig.10 : Results of gB ELISA antibody level detection in mice after HeN21-ΔgG / gI / gE immunization.
[0031] Fig.11 :Observation results of mouse pathological sections.
[0032] Fig.12:Clinical manifestations of pigs after virus challenge. Fig.12 Figure A shows the clinical symptom scores of pigs after virus challenge; Fig.12 Figure B shows the temperature change trend of the experimental pigs after the virus attack; Fig.12 Figure C shows the comparison of average weight gain of test pigs after virus challenge.
[0033] Fig.13 : Monitoring results of neutralizing antibody levels in each group of experimental pigs after vaccination.
[0034] Fig.14 :Protein ELISA antibody levels of piglets after immunization. A: gB ELISA antibody level; B: gE ELISA antibody level results.
[0035] Fig.15 :Determination of viral load in whole blood, throat swab, anal swab and various tissues of piglets after virus challenge.
[0036] Figure A in 15 shows the anticoagulant blood viral load of pigs after virus challenge; Fig.15 Figure B shows the viral load of throat swabs after pigs were challenged with the virus; Fig.15 Figure C shows the viral load of anal swabs after pig challenge; Fig.15 Figure D shows the viral load in various tissues of pigs after virus challenge.
[0037] Fig.16 :Observation of pathological sections of piglets. Fig.16 Figure A in the figure shows the gross lesion observation of the tissue; Fig.16 Figure B shows the histopathological section observation. DETAILED DESCRIPTION
[0038] Description of the sequence listing:
[0039] SEQ ID NO: 1 is the nucleotide sequence of the gG gene deletion portion of the pseudorabies virus epidemic strain gG / gI / gE triple gene deletion strain of the present invention.
[0040] SEQ ID NO: 2 is the nucleotide sequence of the gI / gE gene deletion portion of the pseudorabies virus epidemic strain with a triple gene deletion of gG / gI / gE.
[0041] The present invention is described in detail below with reference to examples. In the following examples, the experimental methods without specifying specific conditions are usually carried out according to the methods described in conventional conditions.
[0042] Example 1
[0043] Experimental Materials and Methods
[0044] 1. Isolation of pseudorabies virus strains, preparation of cells and plasmids:
[0045] The pseudorabies virus PRV HeN21 variant strain is a highly virulent mutant strain isolated by our laboratory in a slaughterhouse in Henan Province in 2021 according to conventional methods. The stable toxicity of this strain is 10 8.59 TCID50 / ml, mouse LD50 is 2.63. BarthaK-61 strain was provided by our laboratory (obtained by conventional methods, the original strain of the virus PRV HeN21, Pseudorabies Virus PRV HeN21, was sent to China. Wuhan. Wuhan University China Type Culture Collection on June 11, 2024, with the collection number CCTCC NO: V202424.). Stable virus titer is 10 7.3 TCID50 / ml.
[0046] The gE monoclonal antibody was stored in our laboratory (obtained by conventional methods).
[0047] The porcine kidney cell PK-15 cell line was preserved by our laboratory, the African green monkey kidney cell Vero cell line was preserved by Wuhan Keqian Biological Co., Ltd., the ST cell line was preserved by Wuhan Keqian Biological Co., Ltd., and the 2B cell line was preserved by Wuhan Keqian Biological Co., Ltd. Plasmid pcDNA3.1(+) was preserved by our laboratory.
[0048] Preparation of enzymes, reagents and consumables:
[0049] PrimeSTAR Mix DNA polymerase and various restriction endonucleases were purchased from TakaRa Biotechnology (Dalian) Co., Ltd. T4 DNA ligase was purchased from Dalian TaKaRa Company; 2×Mix DNA polymerase was purchased from Nanjing Novazon Biotechnology Co., Ltd.; DNA Marker was purchased from TakaRa Biotechnology (Dalian) Co., Ltd. and Nanjing Novazon Biotechnology Co., Ltd.; DH5α competent cells were purchased from Nanjing Novazon Biotechnology Co., Ltd. Green fluorescent protein-labeled goat anti-mouse fluorescent secondary antibody was purchased from Invitrogen, USA.
[0050] DMEM medium powder, Opti-MEM medium, phenol red-free DMEM powder, 2×MEM medium, and trypsin powder were purchased from Gibco. Fetal bovine serum (FBS) was purchased from Hyclone. Low melting point agarose was purchased from Amresco. Penicillin-streptomycin for cells was purchased from Bioshap. Goat anti-mouse HRP-IgG was purchased from Abclone. Goat anti-mouse FITC-IgG was purchased from Beijing Bio-Technology Co., Ltd.
[0051] The general plasmid extraction kit (centrifugal column type) was purchased from Tiangen Biochemical Technology (Beijing) Co., Ltd.; the general column genome extraction kit was purchased from Kangwei Century Biotechnology Co., Ltd.; the agarose gel DNA recovery kit (general centrifugal column type) was purchased from OMEGA; Lipofectamine 2000 liposome transfection reagent was purchased from InvitrogEn; 6-well cell culture plates, T25, T75 and T175 cell culture flasks were purchased from Corning; ultrafiltration tubes were purchased from Millipore; gE protein ELISA kit was purchased from IDEXX Biotechnology; gB protein ELISA blocking kit and 201 adjuvant were purchased from Wuhan Keqian Biological Co., Ltd. MONTANIDE ISA 15A VG veterinary oily adjuvant was purchased from SEPPIC. HRP (horseradish peroxidase)-labeled goat anti-mouse secondary antibody IgG was purchased from Beijing Zhongshan Jinqiao Bioengineering Co., Ltd. Veterinary thermometer was purchased from Shanghai Jiyin Biotechnology Co., Ltd.
[0052] 2. Preparation of culture medium and related reagents:
[0053] DMEM culture medium: dissolve one bag of 1L DMEM powder in 900.0mL triple-distilled water, then add 3.7g NaHCO3, adjust the pH to about 6.8 with concentrated hydrochloric acid, make up to 1000.0mL, filter and sterilize with a 0.22μm filter, divide into portions and store at 4℃ for later use.
[0054] Cell growth medium: Add 10% inactivated fetal bovine serum and 1% penicillin-streptomycin to DMEM culture medium and store at 4°C for later use.
[0055] Cell maintenance medium: Add 2% inactivated newborn calf serum and 1% penicillin-streptomycin to DMEM culture medium and store at 4°C for later use.
[0056] 0.25% pancreatic digestion solution: 2.5g pancreatin, 8.0g NaCl, 0.2g KCl, 1.56g Na2HPO4, 0.2gKH2PO4, add them to 800.0mL of triple-distilled water in sequence. After they are completely dissolved, make up to 1000.0mL, stir at 4℃ overnight, filter and sterilize with a 0.22μm filter, divide them into portions and store them at -20℃ for later use.
[0057] PBS buffer: 8.0g NaCl, 0.2g KCl, 1.56g Na2HPO4, 0.2g KH2PO4, add them to 800mL triple-distilled water in sequence, and after they are completely dissolved, make up to 1000.0mL, steam sterilize at 121℃ for 30min, and store at 4℃ for later use.
[0058] Sucrose solution: The sucrose solution used for gradient centrifugation was prepared according to the mass ratio. A 60% sucrose solution was prepared by adding 60 g of sucrose to 40 mL (i.e., 40 g) of deionized water. 45%, 35%, and 25% sucrose solutions were prepared according to the mass ratio by adding 45 g, 35 g, and 25 g of sucrose to 55 mL, 65 mL, and 75 mL of deionized water, respectively.
[0059] LB liquid medium: 5.0 g tryptone, 2.5 g yeast extract, 5.0 g NaCl, dissolved in about 400 mL deionized water, adjusted the pH to 7.0 after complete dissolution, fixed the volume to 500 mL, steam sterilized at 121°C for 30 min, and stored at room temperature.
[0060] LB solid medium: 5.0 g tryptone, 2.5 g yeast extract, 5.0 g NaCl, 7.5 g agar powder, 500 mL deionized water, sterilize with high pressure steam at 121°C for 30 min, and store at room temperature.
[0061] 0.1% crystal violet: 1% crystal violet, diluted tenfold in PBS.
[0062] Ampicillin solution: Dissolve 1g of ampicillin powder in 10ml of distilled water, filter through a 0.45μm filter for sterilization, and store at -20℃ for later use.
[0063] Example 2: Construction of HeN21-ΔgG / gI / gE gene deletion strain
[0064] (1) Construction of recombinant plasmid pcDNA3.1(+)-△gG / gI / gE
[0065] According to the HeN21 genome map, the upstream homology arm of the gG gene was pulled out, 1154 bp, and named gG-up. NheI and Hind3 restriction sites were added to the left and right ends respectively; the downstream homology arm of gG / upstream homology arm of gE was 1876 bp, named gG-down / gE-up, and Hind3 and BamH1 restriction sites were added to the left and right ends respectively. The downstream homology arm of the gE gene was 1134 bp, named gE-down. EcoRV and Xba1 restriction sites were added to the left and right ends respectively. Takara high-fidelity enzyme amplification was used to sequentially amplify the gG-up, gG-down / gE-up, and gE-down homology arms. After the bands were correct, the products were recovered and digested with pcDNA3.1(+) empty plasmid, gG-UP fragment plasmid, and gG / gI / gE-UP fragment plasmid. After digestion, the correct bands were cut out for gel recovery, connected with T4 ligase at 25°C for 2h, transformed into DH5a, coated with ampicillin-resistant plates, and cultured for 16h before picking single colonies for PCR identification. If the bands were correct, a large number of bacteria were shaken, and the plasmids were extracted and sent to Qingke Biotechnology Company for sequencing. The sequencing results showed that the reaction bands were correct, and finally pcDNA3.1(+)-ΔgG / gI / gE plasmid ( Figure 1 The plasmid was identified using two pairs of identification primers, and the band sizes were 593 and 961 bp, and the positive control band sizes were 1681 bp and 2969 bp, respectively. Figure 2 ).
[0066] Table 1 Primer sequences for homology arm amplification and identification
[0067]
[0068] (2) Construction of PRV HeN21-ΔgG / gI / gE gene-deficient strain
[0069] Virus particles were precipitated by PEG coagulation method, and the HeN21 linearized virus genome was extracted. The gel electrophoresis band size was 150kb and no mixed bands were generated. The concentration was determined by the microplate reader at 1565ng / μL. 2ug HeN21 genome and 2ug pcDNA3.1(+)-ΔgG / gI / gE (concentration 1288ng / μL) plasmid were co-transfected with lipo2000 reagent. After 48h, the lesions were completely collected and the transfection liquid was collected. The F1 generation transfection liquid was diluted 10 times and added to the monolayer of well-growing PK-15 cells. It was mixed with 2×MEM and 2% low melting point agarose in a ratio of 1:1 and evenly covered on the cell surface. After the plaque appeared, a single plaque was picked with a filter tip for PCR identification. The amplified positive band sizes were 593bp and 961bp, respectively. After 7-8 rounds, the positive strain was picked. After 4 rounds of purification, the positive strain was purified to obtain a pure HeN21-ΔgG / gI / gE strain ( Figure 3The extracted nucleic acid was sent to Qingke Biotechnology Co., Ltd. for fragment sequencing. The sequencing results were correct, with no base amino acid mutations, indicating that the HeN21-ΔgG / gI / gE strain was successfully constructed.
[0070] Example 3: Study on biological characteristics of HeN21-ΔgG / gI / gE gene deletion strain
[0071] (1) Study on the genetic stability of HeN21-ΔgG / gI / gE gene-deficient strain
[0072] The purified HeN21-ΔgG / gI / gE deletion strain was continuously propagated on PK-15 cells for 20 generations, and the fragments were sequenced every 5 generations to verify the deletion stability of the gene deletion site. The results showed that no mutations in bases, amino acids, etc. occurred in the nucleic acid fragments of the F5, F10, F15, and F20 generations. The toxin titer was determined every 5 generations, and the results showed that the toxin titer of the deletion virus was stable in a similar range. 8.0 ~10 8.59 The highest virus titer was maintained at a high level ( Figure 4 ).
[0073] (2) IFA test of HeN21-ΔgG / gI / gE gene-deficient strain
[0074] 50ul of HeN21 and HeN21-ΔgG / gI / gE strains were inoculated into a 24-well plate with a monolayer of pk-15 cells, and a blank control was set up. After about 14 hours, when slight lesions appeared, the old culture medium was discarded, and each well of cells was washed three times with PBS, each for 5 minutes; 400ul of formaldehyde fixative was added to each well, at 4°C for 15min; the formaldehyde solution was discarded, and each well of cells was washed three times with PBS, each for 5 minutes; 600ul of PBS buffer containing 5% BSA was added to each well, at 37 ℃ blocking effect for 1h; wash each well of cells with PBS three times, 5 minutes each time; add 400ul of primary antibody (1:500 dilution) to each well and incubate at 37℃ for 1h; discard the primary antibody, wash each well of cells with PBS three times, 5 minutes each time (shaking, 80r); add 400μl of fluorescent secondary antibody (1:500 dilution) to each well in the dark, incubate at 37℃ for 40-50min; wash each well of cells with PBS three times, 5 minutes each time; add 800μl PBS to each well after washing, and observe under a fluorescence microscope. The test results show that HeN21-ΔgG / gI / gE does not emit characteristic fluorescence under red light, which is consistent with the blank control. HeN21 emits specific bright red fluorescence under a microscope, indicating that the gE gene has been successfully deleted, which can realize the differential diagnosis of contemporary vaccines and wild virus infections in my country ( Figure 5 ).
[0075] (3) One-step growth curve determination of HeN21-ΔgG / gI / gE gene deletion strain
[0076] HeN21-ΔgG / gI / gE and HeN21 were inoculated into a monolayer of confluent PK-15 cells at a virus volume of 1 mol. The maintenance medium was replaced 2 hours after inoculation. The virus was collected at 2, 4, 6, 12, 18, 24, 30, and 36 h after inoculation. The TCID 50 The results showed that the proliferation curve of HeN21-ΔgG / gI / gE was similar to that of its parent virus, and there was no significant difference in the proliferation rate. Both reached the maximum titer of 10 at 36 hours after virus infection. 8.55 TCID50 / mL( Figure 6 ), which indicates that the deletion of gG / gI / gE genes, as non-replication essential genes of PRV virus, will not affect the proliferation rate and characteristics of the virus.
[0077] (4) Determination of plaque area of HeN21-ΔgG / gI / gE gene deletion strain
[0078] PRV HeN21 and HeN21-ΔgG / gI / gE were diluted 10 times and inoculated into 6-well cell culture plates covered with monolayer PK-15 cells. After being placed in a 37°C cell culture incubator for 2 hours, the culture medium was discarded and washed twice with PBS. The cells were covered with a 1:1 mixture of 2% low melting point agarose and 2× phenol red-free DMEM. When the cells showed obvious single plaques, they were fixed with 4% paraformaldehyde at room temperature overnight, and the surface agarose was melted at high temperature. Then 0.1% crystal violet was added to each well for staining for 30 minutes, and finally rinsed with water. The plaques were placed under a microscope and photographed to observe the morphology of the plaques, and the area of plaque formation was calculated using Image J. The results showed that the average plaque area of HeN21-ΔgG / gI / gE was 22356um 2 The average plaque area of the parental virus is 38534um 2 Compared with the parental virus, the plaque-forming ability of the deletion virus decreased to a certain extent, but there was no significant difference, which may be related to the fact that the main virulence gene TK was not deleted ( Figure 7 ).
[0079] (5) LD of HeN21-ΔgG / gI / gE gene-deficient strain mice 50 Determination of
[0080] A total of 25 healthy female SPF Balb / c mice aged 4-6 weeks were purchased and divided into 5 groups. The first 4 groups were challenged with 10 2 TCID 50 , 10 3 TCID50 , 10 4 TCID 50 doses of HeN21-ΔgG / gI / gE and 10 4 TCID 50 The mice were treated with HeN21 strains of 100 mg / kg / day, and the last group was a blank control. The clinical symptoms of the mice were observed every day and the deaths were recorded. The observation was continued for 14 days, and the surviving mice were euthanized. The median lethal dose (LD50) of the virus for Balb / c mice was calculated according to the Reed-Muench method. 50 The results showed that mice in the challenge control group began to die on the third day after the challenge, and all died on the fourth day. All dead mice showed obvious symptoms of pseudorabies virus infection, with severe scratching marks on their hind legs and backs, and bloody flesh. 2 TCID 50 In the HeN21-ΔgG / gI / gE group, one animal died on the 8th day. 3 TCID 50 In the HeN21-ΔgG / gI / gE group, 2 and 3 mice died on the 5th and 6th days, respectively. 4 TCID 50 Four mice died on the 4th day and one on the 5th day in the HeN21-ΔgG / gI / gE group. The difference was that the mice in the HeN21-ΔgG / gI / gE group did not show obvious symptoms of pseudorabies virus infection after death, which may be due to internal tissue damage, but the itching symptoms were not obvious. This shows that for this HeN21 virulent variant, even if gI / gE is missing, the LD50 of the missing virus has not decreased significantly, but only decreased from 10 2.63 TCID 50 becomes 10 2.87 TCID 50 ( Figure 8 ), which also shows that the TK gene is the main virulence gene of pseudorabies virus, and the TK gene must be deleted in the development of attenuated live vaccine.
[0081] Example 4: Safety test of HeN21-ΔgG / gI / gE gene-deficient inactivated vaccine
[0082] (1) Safety evaluation of the inactivated HeN21-ΔgG / gI / gE strain in mice
[0083] Twenty-five healthy female SPF Balb / c mice aged 4-6 weeks were randomly divided into 5 groups, 5 mice in each group. Inactivated HeN21-ΔgG / gI / gE strain, Bartha K-61 strain, and commercial PRV variant vaccine were added at 10 7 TCID 50 The HeN21 strain was given at a dose of 10 4TCID 50 Five Balb / c mice were immunized with different doses of HeN21-ΔgG / gI / gE gene deletion inactivated vaccine without needle injection at the back, and a negative control group was set up. The mice were observed for 14 consecutive days and their survival was recorded. The results showed that except for the positive control group, all mice died within a week, and the mice in other groups did not show any abnormalities, indicating that high doses of HeN21-ΔgG / gI / gE gene deletion inactivated vaccine are safe for mice.
[0084] (2) Safety test of HeN21-ΔgG / gI / gE gene-deficient inactivated vaccine in piglets
[0085] Nine 4-6 week-old pseudorabies gB and gE negative piglets were divided into 3 groups. 2×10 8.0 TCID50; Needle-free inoculation inactivated freeze-dried diluted HeN21-ΔgG / gI / gE virus solution 2×10 8.0 TCID50, and set up a blank control, intramuscular injection of 2ml DMEM as an uninfected control group. After inoculation, symptoms were observed daily, and the number of deaths and survivals was recorded for 14 days. Within 2 weeks, all piglets ate normally, were in good spirits, and did not show any adverse symptoms, indicating that high doses of HeN21-ΔgG / gI / gE inactivated virus are safe for piglets.
[0086] Example 5: Immunogenicity test of HeN21-ΔgG / gI / gE gene-deficient inactivated vaccine
[0087] (1) Neutralizing antibody levels in mice after immunization
[0088] After immunization, mice were blooded once a week, and the serum was separated and inactivated at 56℃ for 30 minutes. Neutralizing antibody was determined according to the method. The test results showed that during the entire experimental observation period, the neutralizing antibody level of the HeN21-ΔgG / gI / gE gene-deficient inactivated vaccine group was the highest, reaching 1:178, and the B commercial vaccine control was lower, at 1:162, and the Bartha K-61 was the lowest, at 1:130 ( Fig. 9 ). This indicates that the vaccine prepared from the parental virus has the strongest protective effect against the attack of this mutant strain, and the vaccines prepared from other mutant viruses also have a certain degree of protective effect, while the vaccine prepared from the classic virus has a relatively limited protective effect.
[0089] (2) Protein ELISA antibody levels in immunized mice
[0090] Blood was collected from immunized mice every 7 days to detect the level of gB antibodies in the serum. The test results showed that the gB antibodies of all immunized mice began to turn positive 14 days after immunization and lasted until the last day of the observation period. The gB antibody positive value was the highest on the 7th day of the challenge ( Fig.10). This indicates that the three groups of inactivated vaccines can stimulate mice to produce neutralizing antibodies and have good antigenicity.
[0091] (3) Observation of mouse pathological sections
[0092] After the experiment, the mice in each group that did not die were euthanized, and the lung and brain tissues were taken for pathological sections and HE staining. The pathological tissue sections showed no obvious difference between the lung tissues and brain tissues of the mice in the three immune groups and the blank control group. The lung tissues of the mice in the challenge control group showed obvious interstitial widening, necrosis and shedding of alveolar epithelial cells, and the lung tissue gaps were filled with red blood cells and inflammatory cell infiltration. There was a large amount of red blood cell infiltration in the brain tissue, and astrocytes were produced and vascular cuffing phenomenon ( Fig.11 ).
[0093] (4) Clinical manifestations of pigs after infection
[0094] Fourteen days after the second vaccination, the three immune groups and the challenge control group were infected with 2×10 7 TCID 50 dose of HeN21 strain. The mental state of 20 pigs was closely monitored within one week after the infection. It was found that the pigs in the infection control group began to have persistent high fever on the second day after the infection, began to cough and wheeze on the third day, began to have abdominal breathing on the fifth day, and became unstable on their feet. 60% (3 / 5) died on the seventh day; the body temperature of the recovered pigs began to drop on the sixth day until it returned to normal, but their body weight dropped significantly and the growth trend was slow. Some pigs in the HeN21-ΔgG / gI / gE intramuscular injection group and the commercial vaccine control group had fever, but the high temperature dropped and returned to normal after 3-4 days. There were no obvious adverse reactions after the infection, and the average weight gain within 21 days was 8.65kg and 7.38kg, respectively ( Figure 4-13 , Figure 4-14 , Figure 4-15 ). Comprehensive comparison showed that the HeN21-ΔgG / gI / gE needle-free group had the best immune effect. No fever occurred within one week after the infection, and the feeding and mental state were normal. The average weight gain was 8.83 kg within 21 days, which was better than the existing commercial vaccines ( Fig.12 ).
[0095] (5) Neutralizing antibody levels in immunized piglets
[0096] The neutralizing antibodies in the collected sera were measured to evaluate the immune efficacy of the vaccine. The results showed that neutralizing antibodies were detected in all three immunization groups 21 days after the first immunization. The neutralizing antibody level of the needle-free HeN21-ΔgG / gI / gE test group 21 days after the first immunization was significantly better than that of the intramuscular injection HeN21-ΔgG / gI / gE test group and the commercial PRV variant inactivated vaccine group. The neutralizing antibody level reached 1:256 14 days after the second immunization, which was a full week earlier than the other two test groups, and the high neutralizing antibody level lasted until the last day of the experimental observation period. This shows that the HeN21-ΔgG / gI / gE inactivated vaccine can not only provide long-term protection against the parental variant strains through needle-free immunization, but also produce neutralizing antibodies at the fastest speed ( Fig.13 ).
[0097] (6) Protein ELISA antibody levels in immunized piglets
[0098] The gB ELISA antibody results showed that the three vaccine test pigs showed strong gB positivity on the 21st day after vaccination, and the gB positivity value reached the highest level in the second week of the challenge, and continued to maintain a strong positive value until the last day of the experimental observation. The gEELISA test results showed that the commercial vaccine immunization group began to turn positive for gE antibodies one week after the challenge, while the HeN21-ΔgG / gI / gE intramuscular injection group began to turn positive in the third week after the challenge. The HeN21-ΔgG / gI / gE needle-free group remained gE negative throughout, and only weak gE antibodies were detected on the last day of the observation period ( Fig.14 ).
[0099] (7) Determination of viral load in anal swabs, throat swabs, and whole blood of piglets after virus challenge
[0100] After the virus attack, pigs were collected for anal swabs, throat swabs and anticoagulated blood every 3-4 days, and fluorescent quantitative PCR was performed using gH national standard primers and procedures to monitor virus excretion. The standard curve y = -3.105x + 39.98 was drawn, and sample copies / μL was calculated. The test results showed that within 21 days after the virus attack, the virus excretion was not detected in the pigs' anal swabs, throat swabs and anticoagulated blood. Only a higher level of viral load was detected in the lung and brain tissues of the pigs in the virus attack group after death ( Fig.15 ). This indicates that pigs immunized with the vaccine can better inhibit wild virus infection and reduce the risk of wild virus spread.
[0101] (8) Observation of piglet pathological sections
[0102] The pigs that died in the control group after the virus attack and all the surviving pigs on the last day of the test period were killed, and their lungs, brains, tonsils, larynx and lymph nodes were taken to observe whether there were any lesions. All tissues were divided into two parts, one for making tissue sections and the other for measuring the viral load. The results showed that there was no significant difference between the tissues of all the experimental pigs and the blank control group. On the contrary, the pigs that died from the virus attack had very serious organ bleeding and congestion, mainly manifested as bleeding and congestion of brain tissue, severe color change of lung tissue, congestion of larynx, and suppuration of tonsils (see Fig.16 ).
Claims
1. A pseudorabies virus epidemic strain with three genes deleted, gG, gI, and gE, was named Pseudorabies virus HeN21-ΔgG / gI / gE in Chinese and was deposited in China Center for Type Culture Collection with the deposit number CCTCC NO: V202464.
2. The application of the preparation method with the deposit number CCTCC NO: V202464 in the preparation of an inactivated vaccine containing the three genes gG, gI and gE of the pseudorabies virus epidemic strain deleted.
